NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

INTS

Intensity Therapeutics Inc

Jun 30 • 04:00PM ET

0.3070

Dollar change -0.0130
Percentage change -4.06	%

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE MRK LLY ABBV BMY AMGN GILD REGN VRTX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.06	Insider Own	45.56%	Shs Outstand	15.26M	Perf Week	3.02%
Market Cap	8.00M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	0.00%	Shs Float	14.19M	Perf Month	-21.08%
Enterprise Value	7.20M	PEG	-	EPS next Q	-0.17	Inst Own	9.93%	Short Float	4.65%	Perf Quarter	-84.26%
Income	-15.01M	P/S	-	EPS this Y	40.46%	Inst Trans	-2.95%	Short Ratio	0.53	Perf Half Y	-84.06%
Sales	0.00M	P/B	14.03	EPS next Y	16.75%	ROA	-194.04%	Short Interest	0.66M	Perf YTD	-82.56%
Book/sh	0.02	P/C	8.61	EPS next 5Y	12.46%	ROE	-298.57%	52W High	5.10 -93.98%	Perf Year	-93.77%
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	-24.73% -23.29%	ROIC	-3443.12%	52W Low	0.26 17.99%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.14% 20.15%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-3.49%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.63	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.75	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	0.63	EPS Q/Q	34.31%	SMA20	-20.27%	Beta	3.80	Target Price	3.00
Payout	-	Debt/Eq	0.39	Sales Q/Q	-	SMA50	-44.66%	Rel Volume	3.41	Prev Close	0.32
Employees	16	LT Debt/Eq	0.30	Earnings	May 13 AMC	SMA200	-85.58%	Avg Volume	1.25M	Price	0.31
IPO	Jun 30, 2023	Option/Short	No / No	EPS/Sales Surpr.	-10.00% -	Trades		Volume	4,202,796	Change	-4.06%

Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
08:00AM	Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) (PR Newswire)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -13.17%
Jun-11-25 11:46PM	Intensity Therapeutics, Inc. Announces Pricing of Public Offering (PR Newswire) +15.11% -44.73%
04:06PM	Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
08:30AM	Loading…
08:30AM	Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study (PR Newswire)
May-29-25 08:00AM	Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (PR Newswire) +24.00%
May-28-25 08:00AM	Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon (PR Newswire)
May-13-25 04:06PM	Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) -7.03%
May-06-25 08:00AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France (PR Newswire)
Apr-25-25 08:00AM	Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering (PR Newswire) -37.14%
Apr-21-25 09:40AM	Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-03-25 09:40AM	Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-13-25 04:07PM	Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update (PR Newswire)
Jan-28-25 08:00AM	Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') Following Periodic Review (PR Newswire)
08:00AM	Loading…
Jan-10-25 08:00AM	Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 (PR Newswire) +8.47%
Dec-13-24 08:10AM	Intensity Therapeutics reports positive results of INT230-6 in breast cancer (TipRanks)
Dec-12-24 08:00AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS) (PR Newswire) -12.14%
Nov-21-24 08:00AM	Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire) -8.47%
Nov-18-24 08:00AM	Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS) (PR Newswire)
Nov-13-24 04:06PM	Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -8.55%
Nov-08-24 08:01AM	Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting (PR Newswire)
Oct-31-24 09:00AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) (PR Newswire) +6.56%
Sep-04-24 08:00AM	Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-08-24 04:19PM	Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-09-24 08:01AM	Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma (PR Newswire)
May-15-24 08:01AM	Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors (PR Newswire) +9.28%
May-10-24 10:48AM	Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial (MT Newswires) +6.38%
08:01AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate (PR Newswire)
May-09-24 11:54PM	INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024 (InvestorPlace)
04:08PM	Loading…
04:08PM	Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Apr-02-24 08:01AM	Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 (PR Newswire) -7.82%
Mar-26-24 11:53PM	INTS Stock Earnings: Intensity Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.25%
08:01AM	Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares (GlobeNewswire)
Mar-14-24 04:09PM	Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +15.62%
08:00AM	Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024 (PR Newswire)
Feb-21-24 08:01AM	Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference (PR Newswire)
Jan-03-24 08:01AM	Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program (PR Newswire) -7.84%
Dec-12-23 08:01AM	Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer (PR Newswire)
Dec-08-23 11:12AM	Why Is Intensity Therapeutics (INTS) Stock Up 133% Today? (InvestorPlace) +72.00%
08:30AM	Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS (PR Newswire)
Dec-01-23 08:01AM	Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium (PR Newswire) +28.55%
Nov-13-23 08:01AM	Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update (PR Newswire)
Nov-02-23 07:01AM	Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023 (PR Newswire)
Sep-07-23 08:01AM	Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma (PR Newswire)
Sep-05-23 08:01AM	Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 07:01AM	Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-23 07:01AM	Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire)
Jul-31-23 04:05PM	Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update (GlobeNewswire) +5.14%
Jul-10-23 08:00AM	Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds (PR Newswire)
Jul-05-23 04:15PM	Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds (PR Newswire)
Jun-29-23 08:00PM	Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds (PR Newswire)

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INTS

Intensity Therapeutics Inc

Upgrade your FINVIZ experience